Elisabetta Munzone, A. Fabi, Giuseppe Buono, R. Caputo, Emilia Montagna, Mara Negri, Francesco Nuzzo, Antonella Palazzo, Ida Paris, Luca Conti, Anna Baggi, Jean Marie Franzini, M. de Laurentiis
{"title":"PHASTER 研究:皮下注射 (SC) 培妥珠单抗和曲妥珠单抗固定剂量复方制剂(PH FDC SC)治疗 HER2+ 乳腺癌患者的经济和组织影响","authors":"Elisabetta Munzone, A. Fabi, Giuseppe Buono, R. Caputo, Emilia Montagna, Mara Negri, Francesco Nuzzo, Antonella Palazzo, Ida Paris, Luca Conti, Anna Baggi, Jean Marie Franzini, M. de Laurentiis","doi":"10.1007/s40267-023-01038-5","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":267536,"journal":{"name":"Drugs & Therapy Perspectives","volume":"25 10","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients\",\"authors\":\"Elisabetta Munzone, A. Fabi, Giuseppe Buono, R. Caputo, Emilia Montagna, Mara Negri, Francesco Nuzzo, Antonella Palazzo, Ida Paris, Luca Conti, Anna Baggi, Jean Marie Franzini, M. de Laurentiis\",\"doi\":\"10.1007/s40267-023-01038-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":267536,\"journal\":{\"name\":\"Drugs & Therapy Perspectives\",\"volume\":\"25 10\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs & Therapy Perspectives\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s40267-023-01038-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs & Therapy Perspectives","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40267-023-01038-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients